Image of doctor and patient in exam room

The EPIPEN Savings Card

It’s a savings offer that can provide commercially insured, eligible patients up to $300* in out-of-pocket savings for each EPIPEN 2-PAK® 
and/or EPIPEN JR 2-PAK® carton—up to three cartons (six Auto-Injectors) per prescription fill, so patients have immediate access to an
EPIPEN 2-PAK and/or EPIPEN JR 2-PAK cartons in multiple locations.

Patients can find out if they’re eligible here

The Epinephrine Injection, USP Auto-Injector Savings Card

It's a savings offer that can provide commercially insured, eligible patients up to $25* in out-of-pocket savings for each two-pack carton of the Epinephrine Injection, USP Auto-Injector (The authorized generic to EPIPEN)—up to three cartons (six Auto-Injectors) per prescription fill, so patients have immediate access to a two-pack in multiple locations.

Patients can find out if they’re eligible here

*Certain restrictions apply. See full Terms and Conditions for the EPIPEN Savings Card here and the Epinephrine Injection, USP Auto-Injector Card Savings card here. These savings offers are not valid for patients covered by Medicare, Medicaid or any other federal or state funded healthcare program or where prohibited by law. Mylan Specialty L.P., a Viatris Company reserves the right to amend or end this program at any time without notice.

Viatris' Patient Assistance Program

Viatris has enhanced its Patient Assistance Program to help increase access to EPIPEN. To enroll, patients must complete the Patient Assistance Program form with their physician. Patients can obtain additional information on the program by emailing customer.service@Viatris.com or calling Viatris Customer Relations at 1-800-796-9526 to speak with a representative.

Patient eligibility

To participate in the program, patients must meet the eligibility criteria set forth below:

  • The patient must be a US citizen or a legal resident living in the United States.
  • The patient's gross yearly household income must fall below 400% of the current federal poverty guidelines, based upon family size. Verification documents will be required.

    Approved Documents: 1040, 1040EZ, W2, 4506-T, SSI Statement, Disability Statement, or Statement From Physician, Nurse, or Patient Advocate, or Certified Notarized Statement From the Applicant

  • The patient must meet one of the following conditions:
    • The patient must not have prescription insurance coverage through Medicaid, Medicare Part D, TriCare, a qualified health plan purchased on a state-based, partnership, or federally facilitated exchange, or any other public or private program or insurer. Verification documents will be required.
      Approved Documents: Denial Letter, Termination Statement, Statement From Physician, Nurse, or Patient Advocate, or Certified Notarized Statement From the Applicant.
    • The patient has commercial prescription drug coverage only for generic products and the patient must not have prescription insurance coverage through any state or federally funded program, including, without limitation, Medicare, Medicaid, TriCare or Medicare Part D. Verification documents will be required.
      Approved Documents: Denial Letter, Termination Statement, Statement From Physician or Nurse, or Verification of Applicant's Coverage From the Insurer.
    Download Form

EPIPEN4SCHOOLS®

With the EPIPEN4SCHOOLS program, Mylan Specialty L.P., a Viatris Company offers four free EPIPEN (epinephrine injection, USP) or EPIPEN JR® (epinephrine injection, USP) Auto-Injectors in the form of two EPIPEN 2-PAK cartons, two EPIPEN JR 2-PAK cartons or one 2-Pak of each kind, upon qualification, which includes having a valid prescription, to public and private kindergarten, elementary, middle and high schools in the US. Schools may receive the authorized generic versions of EPIPEN and EPIPEN JR.

To participate in EPIPEN4SCHOOLS, a school nurse or other authorized school representative must visit WWW.EPIPEN4SCHOOLS.COM to download the order and certification form, and then fax or email the form with a valid prescription to 1-973-718-4328 or info@bioridgepharma.com Alternatively, school representatives can call 1-973-845-7600 to speak with a live representative. There is no requirement for a school to purchase additional EPIPEN Auto-Injectors or any other Viatris Inc. products.

Special Offers

Viatris offers Access and Savings Programs for eligible patients. See Terms and Conditions.

There’s only one recommended first line treatment for anaphylaxis.

heading

MORE LESS

Important Safety Information (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN (epinephrine injection, USP) 0.3 mg and EPIPEN JR (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection.

Important Safety Information (the following information applies to both Epipen and its Authorized Generic)

EPIPEN (epinephrine injection, USP) 0.3 mg and EPIPEN JR (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision.

EPIPEN and EPIPEN JR should only be injected into the anterolateral aspect of the thigh. Do not inject intravenously, into buttock, or into digits, hands, or feet. Instruct caregivers to hold the leg of young children firmly in place and limit movement prior to and during injection to minimize risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop symptoms of infection such as persistent redness, warmth, swelling, or tenderness at the injection site.

Epinephrine should be used with caution in patients with heart disease, and in patients who are on drugs that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Indications (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN and EPIPEN JR Auto-Injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EPIPEN and EPIPEN JR Auto-Injectors are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

Click here for Full Prescribing Information for EPIPEN.
Click here for Full Prescribing Information for the Authorized Generic for EPIPEN.

EpiPen_Navigation_Logo

You are now leaving Viatris Inc's website.

The website you are about to access is not owned or controlled by Viatris Inc.

VIATRIS INC. ASSUMES NO RESPONSIBILITY FOR, AND MAKES NO REPRESENTATION AS TO THE ACCURACY OF, ANY CONTENT CONTAINED ON THE WEBSITE YOU ARE ABOUT TO ACCESS.

OK
main-logo

This site is intended for US healthcare professionals.

If you are a patient, please check out our site for patients.

EpiPen_Logo_Navigation

Prescribing Information

EpiPen_Navigation_Logo